OssDsign (OSSD) Strategy Update summary

Strategy and market focus

• ASCENT25 broadens activity from CMF into three orthopaedic segments: craniomaxillofacial, orthobiologics and spine.

• Focus investment on market segments and offerings with commercial and technology synergies; re-evaluate non-core facial reconstructive implants and oral surgery and dental granules.

Strategic priorities

• Win in the US through greater surgeon engagement, KOL activity and expanded sales coverage.

• Build orthobiologics by commercializing the synthetic bone graft substitute added through the Sirakoss acquisition.

• Accelerate product development using existing technology platforms and demonstrate clinical superiority through preclinical and clinical studies and registries.

• Improve operational efficiency through initiatives targeting scale and cost reductions.

Financial ambitions

• Target net sales of SEK 300–400 million in 2025 and positive operating cash flow from 2024.

• Ambitions depend on commercial orders and prices, successful bone graft substitute launch and sales ramp-up, and completion of the announced rights issue, including its over-allotment option.